192 related articles for article (PubMed ID: 31579608)
1. Brodifacoum does not modulate human cannabinoid receptor-mediated hyperpolarization of AtT20 cells or inhibition of adenylyl cyclase in HEK 293 cells.
Sachdev S; Boyd R; Grimsey NL; Santiago M; Connor M
PeerJ; 2019; 7():e7733. PubMed ID: 31579608
[TBL] [Abstract][Full Text] [Related]
2. Absence of Entourage: Terpenoids Commonly Found in
Santiago M; Sachdev S; Arnold JC; McGregor IS; Connor M
Cannabis Cannabinoid Res; 2019; 4(3):165-176. PubMed ID: 31559333
[No Abstract] [Full Text] [Related]
3. Different receptor mechanisms underlying phytocannabinoid- versus synthetic cannabinoid-induced tetrad effects: Opposite roles of CB
Wang XF; Galaj E; Bi GH; Zhang C; He Y; Zhan J; Bauman MH; Gardner EL; Xi ZX
Br J Pharmacol; 2020 Apr; 177(8):1865-1880. PubMed ID: 31877572
[TBL] [Abstract][Full Text] [Related]
4. Cannabichromene is a cannabinoid CB
Udoh M; Santiago M; Devenish S; McGregor IS; Connor M
Br J Pharmacol; 2019 Dec; 176(23):4537-4547. PubMed ID: 31368508
[TBL] [Abstract][Full Text] [Related]
5. A real time screening assay for cannabinoid CB1 receptor-mediated signaling.
Andersen HK; Piroli GG; Walsh KB
J Pharmacol Toxicol Methods; 2018; 94(Pt 1):44-49. PubMed ID: 29730318
[TBL] [Abstract][Full Text] [Related]
6. Cannabidiol skews biased agonism at cannabinoid CB
Navarro G; Reyes-Resina I; Rivas-Santisteban R; Sánchez de Medina V; Morales P; Casano S; Ferreiro-Vera C; Lillo A; Aguinaga D; Jagerovic N; Nadal X; Franco R
Biochem Pharmacol; 2018 Nov; 157():148-158. PubMed ID: 30194918
[TBL] [Abstract][Full Text] [Related]
7. Structural determinants of the partial agonist-inverse agonist properties of 6'-azidohex-2'-yne-delta8-tetrahydrocannabinol at cannabinoid receptors.
Ross RA; Gibson TM; Stevenson LA; Saha B; Crocker P; Razdan RK; Pertwee RG
Br J Pharmacol; 1999 Oct; 128(3):735-43. PubMed ID: 10516656
[TBL] [Abstract][Full Text] [Related]
8. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system.
Schatz AR; Lee M; Condie RB; Pulaski JT; Kaminski NE
Toxicol Appl Pharmacol; 1997 Feb; 142(2):278-87. PubMed ID: 9070350
[TBL] [Abstract][Full Text] [Related]
9. Similarities and differences upon binding of naturally occurring Δ
Raïch I; Rivas-Santisteban R; Lillo A; Lillo J; Reyes-Resina I; Nadal X; Ferreiro-Vera C; de Medina VS; Majellaro M; Sotelo E; Navarro G; Franco R
Pharmacol Res; 2021 Dec; 174():105970. PubMed ID: 34758399
[TBL] [Abstract][Full Text] [Related]
10. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630.
Ross RA; Brockie HC; Stevenson LA; Murphy VL; Templeton F; Makriyannis A; Pertwee RG
Br J Pharmacol; 1999 Feb; 126(3):665-72. PubMed ID: 10188977
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
Felder CC; Joyce KE; Briley EM; Mansouri J; Mackie K; Blond O; Lai Y; Ma AL; Mitchell RL
Mol Pharmacol; 1995 Sep; 48(3):443-50. PubMed ID: 7565624
[TBL] [Abstract][Full Text] [Related]
12. Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship.
Rao GK; Kaminski NE
J Pharmacol Exp Ther; 2006 May; 317(2):820-9. PubMed ID: 16436496
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB
Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R
Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563
[TBL] [Abstract][Full Text] [Related]
14. The effects of beta-arrestin1 deletion on acute cannabinoid activity, brain cannabinoid receptors and tolerance to cannabinoids in mice.
Breivogel CS; Vaghela MS
J Recept Signal Transduct Res; 2015 Feb; 35(1):98-106. PubMed ID: 25779032
[TBL] [Abstract][Full Text] [Related]
15. In vitro determination of the efficacy of illicit synthetic cannabinoids at CB
Sachdev S; Vemuri K; Banister SD; Longworth M; Kassiou M; Santiago M; Makriyannis A; Connor M
Br J Pharmacol; 2019 Dec; 176(24):4653-4665. PubMed ID: 31412133
[TBL] [Abstract][Full Text] [Related]
16. Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal.
Deng L; Guindon J; Cornett BL; Makriyannis A; Mackie K; Hohmann AG
Biol Psychiatry; 2015 Mar; 77(5):475-87. PubMed ID: 24853387
[TBL] [Abstract][Full Text] [Related]
17. Identification of N-arachidonoyl dopamine as a highly biased ligand at cannabinoid CB1 receptors.
Redmond WJ; Cawston EE; Grimsey NL; Stuart J; Edington AR; Glass M; Connor M
Br J Pharmacol; 2016 Jan; 173(1):115-27. PubMed ID: 26398720
[TBL] [Abstract][Full Text] [Related]
18. Suppression of the humoral immune response by cannabinoids is partially mediated through inhibition of adenylate cyclase by a pertussis toxin-sensitive G-protein coupled mechanism.
Kaminski NE; Koh WS; Yang KH; Lee M; Kessler FK
Biochem Pharmacol; 1994 Nov; 48(10):1899-908. PubMed ID: 7986201
[TBL] [Abstract][Full Text] [Related]
19. (-)-Delta9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase.
Bayewitch M; Rhee MH; Avidor-Reiss T; Breuer A; Mechoulam R; Vogel Z
J Biol Chem; 1996 Apr; 271(17):9902-5. PubMed ID: 8626625
[TBL] [Abstract][Full Text] [Related]
20. Finding order in chemical chaos - Continuing characterization of synthetic cannabinoid receptor agonists.
Marusich JA; Wiley JL; Lefever TW; Patel PR; Thomas BF
Neuropharmacology; 2018 May; 134(Pt A):73-81. PubMed ID: 29113898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
